Xin Lang Cai Jing·2026-02-24 08:53Core Viewpoint - The company has received approval from the National Medical Products Administration of China for the expanded age range of its meningococcal polysaccharide conjugate vaccine, MCV4, from children aged 3 months to 3 years to children aged 3 months to 6 years [1] Group 1: Company Developments - The approval allows the company's product, MCV4 (marketed as Manhaixin®), to be administered to a broader age group, enhancing its market potential [1] - Manhaixin® is the first quadrivalent meningococcal conjugate vaccine in China, addressing the gap in high-end vaccines in the country [1] - The innovative advantages of Manhaixin® have led to a strong market performance, with a continuous increase in market share [1] Group 2: Industry Impact - The introduction of Manhaixin® helps to reduce the gap between China and developed countries in the field of meningococcal vaccines [1] - The vaccine provides a better solution for the prevention of meningococcal disease in children aged 6 years and below in China [1]